Fulcrum Therapeutics Inc.

Last updated September 27, 2026

Favorite this organization

Organization details

Legal name: Fulcrum Therapeutics Inc.
Ownership: Public
Status: Active
Sector (GICS): Health Care
SIC code: 2834 — Pharmaceutical Preparations
Jurisdiction of incorporation: Delaware
Headquarters city: Cambridge
Headquarters state / province: Massachusetts
Headquarters country: United States
Fiscal year end: December
Ticker symbol: FULC
Primary stock exchange: Nasdaq

Identifiers

SEC CIK: 0001680581
EIN: 47-4839948
Wikidata ID: Q104481162

Board of directors

Follow this board

Alan Ezekowitz · Director
Since 2023
Alex Sapir · Director · See Remarks
Since 2023
Colin Hill · Director
Since 2024
James A. Geraghty · Director
Since 2023
James J. Collins · Director
Since 2023
Joshua Lehrer-Graiwer · Director
Since 2026
Kate Haviland · Director
Since 2023
Katina Dorton · Director
Since 2023
Rachel K. King · Director
Since 2024
Robert J. Gould · Director · Interim President & CEO
Since 2023
Sonja Banks · Director
Since 2023

Chief executives

Robert J. Gould · Interim President & CEO Interim

Dates unknown

Director election results

Annual meeting of June 24, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Sonja Banks

80.3%
Alan Ezekowitz

97.3%
Colin Hill

97.4%

Board connections

7 of this board's directors also sit on 12 other boards. 12 are in the same sector.

Shared director Other board Same sector

Avalyn Pharma Inc. Same sector
via Kate Haviland
Bicara Therapeutics Inc. Same sector
via Kate Haviland
Crescent Biopharma Inc. Same sector
via Rachel K. King
LENZ Therapeutics Inc. Same sector
via Joshua Lehrer-Graiwer
Novavax Inc. Same sector
via Rachel K. King
Organon & Co. Same sector
via Alan Ezekowitz
Palvella Therapeutics Inc. Same sector
via James A. Geraghty
Prelude Therapeutics Incorporated Same sector
via Katina Dorton
Senti Biosciences Holdings Inc. Same sector
via James J. Collins
Septerna Inc. Same sector
via Alan Ezekowitz
TScan Therapeutics Inc. Same sector
via Katina Dorton
Voyager Therapeutics Inc. Same sector
via James A. Geraghty

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months: $1,485,743; 6 purchases by 2 insiders
Sold, last 12 months: $58,991,621; 8 sales by 4 insiders

Date	Insider	Transaction	Shares	Price	Value
Jul 17, 2026	Kevin Tang 10% owner	Open-market purchase	+50,945	$3.52	$179,326
Jul 16, 2026	Kevin Tang 10% owner	Open-market purchase	+116,671	$3.56	$415,349
Jul 15, 2026	TANG CAPITAL MANAGEMENT LLC 10% owner	Open-market purchase	+107,377	$3.56	$382,262
Jul 14, 2026	TANG CAPITAL MANAGEMENT LLC 10% owner	Open-market purchase	+53,651	$3.56	$190,998
Jul 14, 2026	TANG CAPITAL MANAGEMENT LLC 10% owner	Open-market purchase	+75,952	$3.58	$271,908
Jul 13, 2026	TANG CAPITAL MANAGEMENT LLC 10% owner	Open-market purchase	+12,966	$3.54	$45,900
Jun 26, 2026	Alan Ezekowitz Director	Open-market sale	−18,000	$3.65	$65,700
Feb 2, 2026	Robert J. Gould Director	Open-market sale	−15,000	$10.72	$160,800
Jan 2, 2026	Robert J. Gould Director	Open-market sale	−15,000	$11.87	$178,050
Dec 15, 2025	Oltmans Curtis Gale Officer (Chief Legal Officer)	Open-market sale	−3,452	$12.92	$44,600
Dec 8, 2025	RA Capital Healthcare Fund LP 10% owner	Open-market sale	−1,377,020	$13.33	$18,355,677
Dec 8, 2025	RA Capital Healthcare Fund LP 10% owner	Open-market sale	−2,706,397	$14.28	$38,647,349
Dec 8, 2025	RA Capital Healthcare Fund LP 10% owner	Open-market sale	−91,722	$14.98	$1,373,996
Nov 19, 2025	Robert J. Gould Director	Open-market sale	−15,000	$11.03	$165,450
May 8, 2025	Tourangeau Greg Officer (Principal Accounting Officer)	Open-market sale	−498	$5.06	$2,520

Peers

Compare boards

Organizations in the same sector, closest in location and size first.

3M Company NYSE: MMM · ST Paul, United States Organization ABVC BioPharma Inc. Nasdaq: ABVC · Fremont, United States Organization ACADIA Pharmaceuticals Inc. Nasdaq: ACAD · SAN Diego, United States Organization ADMA Biologics Inc Nasdaq: ADMA · Ramsey, United States Organization

Questions about Fulcrum Therapeutics Inc.

Who is the CEO of Fulcrum Therapeutics Inc.?

Robert J. Gould is Fulcrum Therapeutics Inc.'s Interim President & CEO.

How many directors are on Fulcrum Therapeutics Inc.'s board?

Fulcrum Therapeutics Inc.'s board has 11 directors: Alan Ezekowitz, Alex Sapir, Colin Hill, James A. Geraghty, James J. Collins, Joshua Lehrer-Graiwer, Kate Haviland, Katina Dorton, Rachel K. King, Robert J. Gould and 1 other.

Are Fulcrum Therapeutics Inc. insiders buying or selling shares?

Over the last 12 months, Fulcrum Therapeutics Inc. insiders bought $1.5 million of shares in 6 purchases and sold $59.0 million of shares in 8 sales on the open market, as reported to the SEC on Forms 4 and 5.

How is Fulcrum Therapeutics Inc. connected to…? → Spot something wrong? Report a correction

Embed this board on your site

Paste this where the board should appear. It always shows the current directors and links back here.

<div data-bod-board="fulcrum-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>

Reviews (0)

No reviews yet. Be the first to write one.